Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 03.11.2025 1 Anticancer Res 1 BMC Cancer 1 Br J Cancer 1 Cancer 1 Clin Cancer Res 1 Eur J Radiol 4 Eur Radiol 7 Eur Urol 2 Int J Radiat Oncol Biol Phys 2 Int J Urol 1 J Clin Oncol 1 J Nucl Med 2 Lancet Oncol 2 N Engl J Med 1 Nat Rev Urol 1 Oncogene 2 PLoS One 2 Radiol Imaging Cancer 1 Semin Oncol 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. NAKAI Y, Tanaka N, Onishi K, Goto D, et al
   The Posterior First Approach in Robot-assisted Radical Prostatectomy for Prostate Cancer Reduces Positive Surgical Margins on the Bladder Neck Side.
   Anticancer Res. 2025;45:5177-5184.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. AMIRMOKRI AJ, Loffredo CA, Makambi KH, Dawson NA, et al
   Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.
   BMC Cancer. 2025;25:1645.
   PubMed         Abstract available
   
   

   
   Br J Cancer

3. KLOOTS ISH, Slootbeek PHJ, Tolmeijer SH, van Wilpe S, et al
   Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.
   Br J Cancer. 2025 Oct 31. doi: 10.1038/s41416-025-03243.
   PubMed         Abstract available
   
   

   
   Cancer

4. HUANG MM, Driscoll CB, Handa N, Wahba BM, et al
   Cost-effectiveness of office-based, magnetic resonance imaging-guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial.
   Cancer. 2025;131:e70118.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

5. NYQUIST MD, Nelson P
   Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle.
   Clin Cancer Res. 2025 Oct 29. doi: 10.1158/1078-0432.CCR-25-3045.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

6. YUN Y, Guo J, Shao N, Zhang X, et al
   Synthetic MRI as a T2WI alternative in bp-MRI: comparable image quality and improved PI-RADS performance.
   Eur J Radiol. 2025;193:112414.
   PubMed         Abstract available
   
   

   
   Eur Radiol

7. RATA M, Tunariu N, Jiang Y, Hughes J, et al
   Serial T(1) and T(2) measurements of metastatic bone lesions in prostate cancer patients: MR fingerprinting vs conventional MRI.
   Eur Radiol. 2025 Oct 24. doi: 10.1007/s00330-025-12071.
   PubMed         Abstract available
   
   
8. PONSIGLIONE A, Cimadamore A, Girometti R
   Unmasking "unconventional" prostate cancer histologies: A real diagnostic challenge?
   Eur Radiol. 2025 Oct 31. doi: 10.1007/s00330-025-12066.
   PubMed        
   
   
9. CHENG Y, Shen L, Liao Q, Qin J, et al
   Multi-reader evaluation of the prostate imaging quality score system version 2 (PI-QUAL V2) and its clinical application.
   Eur Radiol. 2025;35:7027-7039.
   PubMed         Abstract available
   
   
10. IVEY MC, Deivasigamani S, Kotamarti S, Mottaghi M, et al
    External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound.
    Eur Radiol. 2025;35:7004-7012.
    PubMed         Abstract available
    
    

    
    Eur Urol

11. PILATZ A, Cornford P, Bonkat G, Kranz J, et al
    Transperineal Prostate Biopsy Without Antibiotic Prophylaxis: The New Gold Standard? Recommendations from the European Association of Urology Guidelines on Prostate Cancer and Urological Infections.
    Eur Urol. 2025 Oct 23:S0302-2838(25)04737-2. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
12. CHA E, Lin Z, Lu J, Oliveira LD, et al
    Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy.
    Eur Urol. 2025 Oct 23:S0302-2838(25)00495-6. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
13. DEMOGEOT N, Supiot S, Sargos P
    Reply to Federico Iori, Emanuele Ali, and Cinzia Iotti's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostat
    Eur Urol. 2025 Oct 23:S0302-2838(25)04740-2. doi: 10.1016/j.eururo.2025.09.4175.
    PubMed        
    
    
14. DEMOGEOT N, Supiot S, Sargos P
    Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi's Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Local
    Eur Urol. 2025 Oct 23:S0302-2838(25)04741-4. doi: 10.1016/j.eururo.2025.09.4176.
    PubMed        
    
    
15. FETTKE H, Kostos L, Docanto M, Bukczynska P, et al
    Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617.
    Eur Urol. 2025 Oct 29:S0302-2838(25)00501-9. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
16. KARPINSKI MJ, Hoberuck S, Fendler WP, Civan C, et al
    Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.
    Eur Urol. 2025 Oct 29:S0302-2838(25)04773-6. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
17. CORNFORD P
    Reply to Andrew J. Vickers' Letter to the Editor re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 2025;87:619-21.
    Eur Urol. 2025 Oct 30:S0302-2838(25)04723-2. doi: 10.1016/j.eururo.2025.09.4163.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

18. JONGEN CA, Heijmen BJ, Incrocci L, Heemsbergen WD, et al
    Radiobiological Modeling for Acute Proctitis after Conventional and Hypofractionated Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Oct 23:S0360-3016(25)06385.
    PubMed         Abstract available
    
    
19. ZACHARAKI EI, Breto AL, Algohary A, Wallaengen V, et al
    Integration of Habitat Risk Score (HRS) in Radiotherapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Oct 23:S0360-3016(25)06347.
    PubMed         Abstract available
    
    

    
    Int J Urol

20. AIZAWA R, Mizowaki T
    Editorial Comment on "Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer".
    Int J Urol. 2025 Oct 29. doi: 10.1111/iju.70272.
    PubMed        
    
    
21. URABE F
    Editorial Comment on Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
    Int J Urol. 2025 Oct 26. doi: 10.1111/iju.70269.
    PubMed        
    
    

    
    J Clin Oncol

22. FLESHNER NE, Bernardino RM, Izawa J, Drachenberg D, et al
    Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.
    J Clin Oncol. 2025 Oct 30:JCO2501070. doi: 10.1200/JCO-25-01070.
    PubMed         Abstract available
    
    

    
    J Nucl Med

23. DJAILEB L, Farolfi A, Rauscher I, Haghighatian M, et al
    Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [(177)Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2025 Oct 30:jnumed.125.270239. doi: 10.2967/jnumed.125.270239.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

24. SMITH M, Piulats J, Todenhofer T, Lee JL, et al
    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2025;26:1489-1500.
    PubMed         Abstract available
    
    
25. O'REILLY M, McDermott R
    CYCLONE 2: no impact on prostate cancer forecast.
    Lancet Oncol. 2025;26:1400-1402.
    PubMed        
    
    

    
    N Engl J Med

26. ROOBOL MJ, de Vos II, Mansson M, Godtman RA, et al
    European Study of Prostate Cancer Screening - 23-Year Follow-up.
    N Engl J Med. 2025;393:1669-1680.
    PubMed         Abstract available
    
    
27. VICKERS A
    Early Detection of Prostate Cancer - Time to Fish or Cut Bait.
    N Engl J Med. 2025;393:1742-1743.
    PubMed        
    
    

    
    Nat Rev Urol

28. SONG D, Malshy K, Messing EM, Joseph JV, et al
    Excluding PLND in favourable intermediate-risk prostate cancer: a PSMA-PET-directed perspective.
    Nat Rev Urol. 2025 Oct 24. doi: 10.1038/s41585-025-01105.
    PubMed        
    
    

    
    Oncogene

29. CHERIF C, Nguyen DT, Paris C, Le TK, et al
    Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
    Oncogene. 2025 Oct 28. doi: 10.1038/s41388-025-03614.
    PubMed        
    
    

    
    PLoS One

30. ENGELAGE L, Behnel N, Lumiani A, Tamalunas A, et al
    Comparison of PSA Values from capillary dried blood spot analysis and venous serum samples.
    PLoS One. 2025;20:e0335448.
    PubMed         Abstract available
    
    
31. LEE J, Song M, Leem S, Kim JY, et al
    Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data.
    PLoS One. 2025;20:e0335459.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

32. YUAN L, Zhang J, Ma L, Xia Y, et al
    MRI-based Habitat Imaging for Noninvasive Prediction of High-Grade Prostate Cancer.
    Radiol Imaging Cancer. 2025;7:e240395.
    PubMed         Abstract available
    
    
33. WAIRIRI L, Folkert MR
    Treatment-Response Prediction for Metastatic Castrate-Resistant Prostate Cancer Using PSMA PET.
    Radiol Imaging Cancer. 2025;7:e259030.
    PubMed        
    
    

    
    Semin Oncol

34. SIGORSKI D, Kasprzyk-Pawelec A, Michalak M, Sosnowski R, et al
    The nervous system in prostate cancer: A basic science and clinical perspective.
    Semin Oncol. 2025;53:152425.
    PubMed         Abstract available
    
    

    
    Urology

35. SLOTA J, Lee Z
    Reply to Editorial Comment on "Economic Burden of Urinary Incontinence in Men with Prostate Cancer: Results from the Medical Expenditure Panel Survey (2016-2021)".
    Urology. 2025 Oct 23:S0090-4295(25)01031-3. doi: 10.1016/j.urology.2025.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.